Innovation Hubs as Strategic Enablers of Advanced Therapy Medicinal Product (ATMP) Development in Emerging Markets
Abstract
<h2>Research Aim, Objectives, and Questions</h2> <h3>Critical Examination of Innovation Hubs as Catalysts for ATMP Development</h3> <p>This research aims to critically explore how innovation hubs in emerging markets function as strategic enablers for the acceleration of Advanced Therapy Medicinal Products (ATMPs), with a particular focus on the interaction between policy frameworks, investment dynamics, and cross-sectoral collaboration.</p> <h3>Research Objectives for Evaluating Innovation Hub Performance and Effectiveness</h3> <ul> <li>To investigate the structural and functional configurations of innovation hubs that support ATMP development in selected emerging markets.</li> <li>To analyse the influence of national innovation policies, regulatory environments, and institutional governance on the ability of hubs to accelerate ATMP pipelines.</li> <li>To assess the role of investment flows, funding models, and public-private partnerships (PPPs) in enhancing the operational capacity and performance of innovation hubs.</li> <li>To identify context-specific barriers and enablers that shape the effectiveness of innovation hubs in translating ATMP research into commercially viable and clinically impactful therapies.</li> </ul> <h3>Research Questions Guiding the Investigation of Innovation Hub Contributions to ATMP Acceleration</h3> <ul> <li>In what ways are innovation hubs in India, Brazil, and China structurally organised and functionally designed to support the development and acceleration of ATMPs?</li> <li>How do national policy instruments and regulatory regimes impact the strategic effectiveness of innovation hubs in advancing ATMP innovation?</li> <li>What is the role of financial mechanisms in shaping innovation hub performance and ATMP translation outcomes?</li> <li>What challenges and success factors do innovation hubs face in resource-constrained contexts?</li> </ul>